[11C]-PIB imaging in patients with Parkinson's disease:: Preliminary results

被引：35

作者：

Johansson, A. ^{[1
]}

Savitcheva, I. ^{[2
]}

Forsberg, A. ^{[3
]}

Engler, H. ^{[2
]}

Langstrom, B. ^{[4
]}

Nordberg, A. ^{[3
]}

Askmark, H. ^{[1
]}

机构：

[1] Univ Hosp, Dept Neurol, SE-75185 Uppsala, Sweden

[2] Uppsala Univ, Dept Nucl Med, SE-75185 Uppsala, Sweden

[3] Karolinska Univ, Huddinge Hosp, Dept Neurobiol, Care Sci & Soc,Div Mol Neuropharmacol,Karolinska, SE-14186 Stockholm, Sweden

[4] Uppsala Imanet AB, GE Healthcare, SE-75109 Uppsala, AB, Sweden

来源：

PARKINSONISM & RELATED DISORDERS | 2008年 / 14卷 / 04期

关键词：

Parkinson's disease; PET; PIB; amyloid; Lewy bodies; alpha-synuclein;

D O I：

10.1016/j.parkreldis.2007.07.010

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[C-11]-PIB positron emission tomography ([C-11]-PIB PET) is a sensitive marker of amyloid in Alzheimer's disease (AD), but its specificity has not been fully evaluated. Vascular amyloid-beta deposition is common in Parkinson's disease (PD) and alpha-synuclein, the major component of the Lewy bodies in PD, forms amyloid fibrils. We investigated five apparently cognitively normal PD patients with [C-11]PIB PET. The results were compared to 16 patients with AD and six healthy controls from a previous study. [C-11]-PIB retention was not significantly increased in our patients who all had early stage PD. Further Studies of more advanced PD patients are warranted. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：345 / 347

页数：3

共 16 条

[1] Molecular imaging with Pittsburgh compound B confirmed at autopsy - A case report
Bacskai, Brian J.
Frosch, Matthew P.
Freeman, Stefanie H.
Raymond, Scott B.
Augustinack, Jean C.
Johnson, Keith A.
Irizarry, Michael C.
Klunk, William E.
Mathis, Chester A.
DeKosky, Steven T.
Greenberg, Steven M.
Hyman, Bradley T.
Growdon, John H.
[J]. ARCHIVES OF NEUROLOGY, 2007, 64 (03) : 431 - 434
[2] Burn DJ, 2006, J NEURAL TRANSM-SUPP, P361
[3] Functional imaging in Parkinson's disease: activation studies with PET, fMRI and SPECT
Ceballos-Baumann, AO
[J]. JOURNAL OF NEUROLOGY, 2003, 250 (Suppl 1) : 15 - 23
[4] Lewy body cortical involvement may not always predict dementia in Parkinson's disease
Colosimo, C
Hughes, AJ
Kilford, L
Lees, AJ
[J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (07) : 852 - 856
[5] Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid
Conway, KA
Harper, JD
Lansbury, PT
[J]. BIOCHEMISTRY, 2000, 39 (10) : 2552 - 2563
[6] Two-year follow-up of amyloid deposition in patients with Alzheimer's disease
Engler, Henry
Forsberg, Anton
Almkvist, Ove
Blomquist, Gunnar
Larsson, Emma
Savitcheva, Irina
Wall, Anders
Ringheim, Anna
Langstrom, Bengt
Nordberg, Agneta
[J]. BRAIN, 2006, 129 : 2856 - 2866
[7] Fahn S, 1987, Recent Dev. Park. Dis, P153
[8] PET imaging of amyloid deposition in patients with mild cognitive impairment
Forsberg, Anton
Engler, Henry
Almkvist, Ove
Blomquist, Gunnar
Hagman, Goran
Wall, Anders
Ringheim, Anna
Langstrom, Bengt
Nordberg, Agneta
[J]. NEUROBIOLOGY OF AGING, 2008, 29 (10) : 1456 - 1465
[9] Hamilton RL, 2000, BRAIN PATHOL, V10, P378
[10] Prevalence of Alzheimer lesions in Parkinson's disease
Jellinger, KA
[J]. MOVEMENT DISORDERS, 2003, 18 (10) : 1207 - 1208

← 1 2 →